Diabetic Macular Edema: Pathophysiology and Novel Therapeutic Targets

Ophthalmology

Volumn 122, Issue 7, 2015, Pages 1375-1394

  Das, Arup ^a,b   McGuire, Paul G ^a   Rangasamy, Sampathkumar ^c  

^a UNIVERSITY OF NEW MEXICO SCHOOL OF MEDICINE   (United States)

^b NEW MEXICO VA HEALTH CARE SYSTEM   (United States)

^c TGEN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALG 1001; ANGIOPEPTIN; ANGIOPOIETIN 2 INHIBITOR; BETAMETHASONE; CHEMOKINE INHIBITOR; CHOLINERGIC RECEPTOR BLOCKING AGENT; CYCLODEXTRIN; DANAZOL; DARAPLADIB; DEXAMETHASONE; ERYTHROPOIETIN; EXENDIN 4; ICO 007; INTERLEUKIN INHIBITOR; LOTEPREDNOL; LYMPHOCYTE FUNCTION ASSOCIATED ANTIGEN 1; MECAMYLAMINE; MINOCYCLINE; NONSTEROID ANTIINFLAMMATORY AGENT; PHOSPHOTRANSFERASE INHIBITOR; PROTEIN KINASE C INHIBITOR; PROTEINASE INHIBITOR; RTP 801; SQUALAMINE; SRC KINASE INHIBITOR; TEPROTUMUMAB; TUMOR NECROSIS FACTOR INHIBITOR; UNCLASSIFIED DRUG; UNINDEXED DRUG; VASCULAR ADHESION PROTEIN 1 INHIBITOR; VASCULOTROPIN INHIBITOR; ANGIOGENESIS INHIBITOR; VASCULOTROPIN A; VEGFA PROTEIN, HUMAN;

ARTICLE; CLINICAL FEATURE; DIABETIC MACULAR EDEMA; DRUG TARGETING; HUMAN; HYPERLIPIDEMIA; IN VITRO STUDY; IN VIVO STUDY; LOW LEVEL LASER THERAPY; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROLIFERATIVE DIABETIC RETINOPATHY; RISK FACTOR; STEM CELL TRANSPLANTATION; TREATMENT INDICATION; TREATMENT RESPONSE; ANIMAL; ANTAGONISTS AND INHIBITORS; DIABETIC RETINOPATHY; MACULAR EDEMA;

ANGIOGENESIS INHIBITORS; ANIMALS; DIABETIC RETINOPATHY; HUMANS; MACULAR EDEMA; RISK FACTORS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84937739093     PISSN: 01616420     EISSN: 15494713     Source Type: Journal    
DOI: 10.1016/j.ophtha.2015.03.024     Document Type: Review

References (134)

1. IDF Diabetes Atlas 6th ed. 2013 International Diabetes Federation Brussels, Belgium
2. J.W. Yau, S.L. Rogers, R. Kawasaki, and et al. Meta-Analysis for Eye Disease (META-EYE) study group. Global prevalence and risk factors of diabetic retinopathy Diabetes Care 35 2012 556 564
3. R. Klein, B.E.K. Klein, S.E. Moss, and K.J. Cruickshanks The Wisconsin Epidemiologic Study of Diabetic Retinopathy: XV: the long-term incidence of macular edema Ophthalmology 102 1995 7 16
4. N.H. White, W. Sun, P.A. Cleary DCCT-EDIC Research Group Effect of prior intensive therapy in type 1 diabetes on 10-year progression of retinopathy in the DCCT/EDIC: comparison of adults and adolescents Diabetes 59 2010 1244 1253
5. R. Klein, B.E. Klein, S.E. Moss, and K.J. Cruickshanks The Wisconsin Epidemiologic Study of Diabetic Retinopathy. XV. The long-term incidence of diabetic macular edema Ophthalmology 102 1995 7 16
6. Frank RN. Etiologic mechanisms in diabetic retinopathy. In: Ryan SJ, ed. Retina. Vol 2. St. Louis, MO: Mosby; 2001:1259-94.
7. Early Treatment Diabetic Retinopathy Study Research Group Photocoagulation for diabetic macular edema. ETDRS Report No. 1 Arch Ophthalmol 10 1985 1796 1806
8. C.P. Wilkinson, F.L. Ferris 3rd, R.E. Klein, and et al. Proposed international clinical diabetic retinopathy and diabetic macular edema disease severity of scales Ophthalmology 110 2003 1677 1682
9. D.J. Browning, A.R. Glassman, L.P. Aiello, and et al. Optical coherence tomography measurements and analysis methods in optical coherence tomography studies of diabetic macular edema Ophthalmology 115 2008 1366 1371
10. D.J. Browning, A.R. Glassman, L.P. Aiello, and et al. Relationship between optical coherence tomography-measured central retinal thickness and visual acuity in diabetic macular edema Ophthalmology 115 2007 525 536
11. R. Varma, N.M. Bressler, Q.V. Doan, and et al. Prevalence and risk factors for diabetic macular edema in the United States JAMA Ophthalmol 132 2014 1334 1340
12. R. Klein, B.E. Klein, S.E. Moss, and et al. The Wisconsin Epidemiologic Study of Diabetic Retinopathy. II. Prevalence and risk of diabetic retinopathy when age at diagnosis is less than 30 years Arch Ophthalmol 102 1984 520 526
13. R. Klein, B.E. Klein, S.E. Moss, and et al. The Wisconsin Epidemiologic Study of Diabetic Retinopathy. III. Prevalence and risk of diabetic retinopathy when age at diagnosis is 30 or more years Arch Ophthalmol 102 1984 527 532
14. H.A. Keenan, T. Costacou, J.K. Sun, and et al. Clinical factors associated with resistance to microvascular complications in diabetic patients of extreme disease duration: the 50-year medalist study Diabetes Care 30 2007 1995 1997
15. J.K. Sun, H.A. Keenan, J.D. Cavallerano, and et al. Protection from retinopathy and other complications in patients with type 1 diabetes of extreme duration: the Joslin 50-year medalist study Diabetes Care 34 2011 968 974
16. The Diabetes Control and Complications Trial Research Group The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus N Engl J Med 329 1993 977 986
17. P. King, I. Peacock, and R. Donnelly The UK Prospective Diabetes Study (UKPDS): clinical and therapeutic implications for Type 2 diabetes Br J Clin Pharmacol 48 1999 643 648
18. R.N. Frank Diabetic retinopathy N Engl J Med 350 2004 48 58
19. N.H. White, W. Sun, P.A. Cleary Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group Prolonged effect of intensive therapy on the risk of retinopathy complications in patients with type 1 diabetes mellitus: 10 years after the Diabetes Control and Complications Trial Arch Ophthalmol 126 2008 1707 1715
20. F. Miao, Z. Chen, S. Genuth, and et al. Evaluating the role of epigenetic histone modifications in the metabolic memory if type diabetes Diabetes 63 2014 1748 1762
21. The ACCORD Study Group, and ACCORD Eye Study Group Effects of medical therapies on retinopathy progression in type 2 diabetes N Engl J Med 363 2010 233 244
22. J.W. Beulens, A. Patel, J.R. Vingerling, and et al. Effects of blood pressure lowering and intensive glucose control on the incidence and progression of retinopathy in patients with type 2 diabetes mellitus: a randomised controlled trial Diabetologia 52 2009 2027 2036
23. R. Benarous, M.B. Sasongko, S. Qureshi, and et al. Differential association of serum lipids with diabetic retinopathy and diabetic macular edema Invest Ophthalmol Vis Sci 52 2011 7464 7469
24. E.Y. Chew, M.L. Klein, F.L. Ferris 3rd, and et al. Association of elevated serum lipid levels with retinal hard exudate in diabetic retinopathy. Early Treatment Diabetic Retinopathy Study (ETDRS) Report 22 Arch Ophthalmol 114 1996 1079 1084
25. A.C. Keech, P. Mitchell, P.A. Summanen, and et al. Effect of fenofibrate on the need for laser treatment for diabetic retinopathy (FIELD study): a randomised controlled trial Lancet 370 2007 1687 1697
26. S.F. Abcouwer Direct effects of PPARα agonists on retinal inflammation and angiogenesis may explain how fenofibrate lowers risk of severe proliferative diabetic retinopathy Diabetes 62 2013 36 38
27. T.D. Panagiotoglou, E.S. Ganotakis, G.D. Kymionis, and et al. Atorvastatin for diabetic macular edema in patients with diabetes mellitus and elevated serum cholesterol Ophthalmic Surg Lasers Imaging 41 2010 316 322
28. S. Narang, S. Sood, B. Kaur, and et al. Atorvastatin in clinically-significant macular edema in diabetics with a normal lipid profile Nepal J Ophthalmol 4 2012 23 28
29. The Diabetes Control and Complications Trial research Group Clustering of long-term complications in families with diabetes in the diabetes control and complications trial Diabetes 46 1997 1829 1839
30. Z. Tong, Z. Yang, S. Patel, and et al. Promoter polymorphism in severe diabetic eye and kidney complications Proc Natl Acad Sci U S A 105 2008 6998 7003
31. J.Z. Kuo, T.Y. Wong, and J.I. Rotter Challenges in elucidating the genetics of diabetic retinopathy JAMA Ophthalmol 132 2014 96 107
32. C. Tiruppathi, A.B. Malik, P.J. Del Vecchio, and et al. Electrical method for detection of endothelial cell shape change in real time: assessment of endothelial barrier function Proc Natl Acad Sci U S A 89 1992 7919 7923
33. L. Tang, C.A. Lee, D. Yunpeng, and et al. My D88 pathways in leukocytes affect the retina in diabetes PLoS One 8 2013 e68871
34. A.J. Barber, D.A. Antonetti, T.S. Kern, and et al. The Ins2Akita mouse as a model of early retinal complications in diabetes Invest Ophthalmol Vis Sci 46 2005 2210 2218
35. A. Chronopoulos, E. Beglova, S. Roy, and et al. Development of a non-human primate model of diabetic retinopathy. Invest Ophthalmol Vis Sci 51 2011 E-Abstract 5961/A110
36. B.B. Gao, A. Clermont, Rook, and et al. Extracellular carbonic anhydrase mediates hemorrhagic retinal and cerebral vascular permeability through prekallikrein activation Nat Med 13 2007 181 188
37. R. Robinson, V.A. Barathi, and S.S. Chaurasia Update on animal models of diabetic retinopathy: from molecular approaches to mice and higher mammals Dis Model Mech 5 2012 444 456
38. B.A. Berkowitz, D. Bissig, Y. Ye, and et al. Evidence for diffuse central retinal edema in vivo in diabetic male Sprague Dawley rats PLoS One 7 2012 e29619
39. M. Brownlee The pathobiology of diabetic complications: a unifying mechanism Diabetes 54 2005 1615 1625
40. S. Rangasamy, R. Srinivasan, P.G. McGuire, and A. Das Diabetic macular edema: molecular mechanisms A. Das, T. Friberg, Therapy for Ocular Angiogenesis 2011 Wolters Kluwer Philadelphia, PA 88 99
41. D.A. Antonetti, A.J. Barber, S. Khin, and et al. Vascular permeability in experimental diabetes is associated with reduced endothelial occludin content Diabetes 47 1998 1953 1959
42. D. Navaratna, P.G. McGuire, G. Menicucci, and A. Das Proteolytic degradation of VE-cadherin alters the blood-retinal barrier in diabetes Diabetes 56 2007 2380 2387
43. D.A. Antonetti, A.J. Barber, L.A. Hollinger, and et al. Vascular endothelial growth factor induces rapid phosphorylation of tight junction proteins occludin and zonula occludens J Biol Chem 274 1999 23463 23467
44. M. Mizutani, T.S. Kern, and M. Lorenzi Accelerated death of retinal microvascular cells in human and experimental diabetic retinopathy J Clin Invest 15 1996 2883 2890
45. T. Kuwabara, and D.G. Cogan Retinal vascular patterns. VI. Mural cells of the retinal capillaries Arch Ophthalmol 69 1963 492 502
46. A. Das, R.N. Frank, M.L. Weber, and et al. ATP causes retinal pericytes to contract in vitro Exp Eye Res 46 1988 349 362
47. R.N. Frank Etiologic mechanisms in diabetic retinopathy S.J. Ryan, Retina Volume II 2006 Elsevier Mosby Philadelphia, PA 1241 1270
48. P. Lindahl, B.R. Johansson, P. Levéen, and et al. Pericyte loss and microaneurysm formation in PDGF-B deficient mice Science 277 1997 242 245
49. A. Orlidge, and P.A. D'Amore Inhibition of capillary cell growth by pericytes and smooth muscle cells J Cell Biol 105 1987 1455 1462
50. A. Das, R.N. Frank, N.L. Zhang, and et al. Increases in collagen type IV and laminin in galactose-induced retinal capillary basement membrane thickening - prevention by an aldose reductase inhibitor Exp Eye Res 50 1990 269 280
51. D.A. Antonetti, R. Klein, and T.W. Gardner Diabetic retinopathy N Engl J Med 366 2012 1227 1239
52. G.J. Del Zoppo The neurovascular unit in the setting of stroke J Intern Med 267 2010 156 171
53. M. Mizutani, C. Gerhardinger, and M. Lorenzi Muller cell changes in human diabetic retinopathy Diabetes 47 1998 445 449
54. G.R. Jackson, I.U. Scott, D.A. Quillen, and et al. Inner retinal visual dysfunction is a sensitive marker of nonproliferative diabetic retinopathy Br J Ophthalmol 96 2012 699 703
55. A.J. Barber A new view of diabetic retinopathy: a neurodegenerative disease of the eye Prog Neuropsychopharmacol Biol Psychiatry 27 2003 283 290
56. T.E. de Gooyer, K.A. Stevenson, P. Humphries, and et al. Retinopathy is decreased during experimental diabetes in a mouse model of outer retinal degeneration Invest Ophthalmol Vis Sci 47 2006 5561 5568
57. G.B. Arden The absence of diabetic retinopathy in patients with retinitis pigmentosa: implications for pathophysiology and possible treatment Br J Ophthalmol 85 2001 366 370
58. Y. Du, A. Veenstra, K. Palczewski, and T.S. Kern Photoreceptor cells are major contributors to diabetes-induced oxidative stress and local inflammation in the retina Proc Natl Acad Sci U S A 110 2013 16586 16591
59. S. Vinores, C. Gadegbaku, P.A. Campochiaro, and et al. Immunolocalization of blood-retinal barrier breakdown in human diabetics Am J Pathol 134 1989 231 235
60. H.Z. Xu, and Y.Z. Le Significance of outer blood-retina barrier breakdown in diabetes and ischemia Invest Ophthalmol Vis Sci 52 2011 2160 2164
61. A.P. Adamis, and A.J. Berman Immunological mechanisms in the pathogenesis of diabetic retinopathy Semin Immunopathol 30 2008 65 84
62. K. Miyamoto, S. Khosrof, S.E. Bursell, and et al. Prevention of leukostasis and vascular leakage in streptozotocin-induced diabetic retinopathy via intercellular adhesion molecule-1 inhibition Proc Natl Acad Sci U S A 96 1999 10836 10841
63. A.M. Joussen, V. Poulaki, M.L. Le, and et al. A central role of inflammation in the pathogenesis of diabetic retinopathy FASEB J 18 2004 1450 1452
64. D.S. McLeod, D.J. Lefer, C. Merges, and G.A. Lutty Enhanced expression of intracellular adhesion molecule-1 and P-selectin in the diabetic human retina and choroid Am J Pathol 147 1995 642 653
65. S.Y. Kim, S.Y. Kim, M.A. Johnson, and et al. Neutrophils are associated with capillary closure in spontaneously diabetic monkey retinas Diabetes 54 2005 1534 1542
66. S. Rangasamy, P.G. McGuire, C. Franco Nitta, and et al. Chemokine mediated monocyte trafficking into the retina: role of inflammation in alteration of the blood-retinal barrier diabetic retinopathy PLoS One 9 2014 e108508
67. H. Funatsu, H. Noma, T. Mimura, and et al. Association of vitreous inflammatory markers in diabetic macular edema Ophthalmology 116 2009 73 79
68. R.N. Frank Systemic therapies for diabetic retinopathy: the ACCORD Eye Study (editorial) Ophthalmology 121 2014 2295 2296
69. E. Chew, M.D. Davis, R. Danis, and et al. The effects of medical management on the progression of diabetic retinopathy in persons with type 2 diabetes: the Action to Control Cardiovascular Risk in Diabetes (ACCORD) Eye Study Ophthalmology 121 2014 2443 2451
70. E.H. Ryan Jr., D.P. Han, R.C. Ramsay, and et al. Diabetic macular edema associated with glitazone use Retina 26 2006 562 570
71. Y. Miura, F. Treumer, A. Klettner, and et al. VEGF and PEDF secretions over time following various laser irradiations on an RPE organ culture Invest Ophthalmol Vis Sci 51 2010 469
72. Diabetic Retinopathy Clinical Research Network Randomized trial evaluating ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema Ophthalmology 117 2010 1064 1077
73. Diabetic Retinopathy Clinical Research Network Intravitreal ranibizumab for diabetic macular edema with prompt versus deferred laser treatment: three year randomized trial results Ophthalmology 119 2012 2312 2318
74. J. Figueira, J. Khan, S. Nunes, and et al. Prospective randomised controlled trial comparing sub-threshold micropulse diode laser photocoagulation and conventional green laser for clinically significant diabetic macular edema Br J Ophthalmol 93 2009 1341 1344
75. Diabetic Retinopathy Clinical Research Network Vitrectomy outcomes in eyes with diabetic macular edema and vitreomacular traction Ophthalmology 117 2010 1087 1093
76. A Multicenter Study to Compare Multiple Doses of Intravitreal Microplasmin Versus Sham Injection for Treatment of Patients With Diabetic Macular Edema (DME) (MIVI-II). Available at: http://clinicaltrials.gov/ct2/show/NCT00412451. Accessed November 3, 2014.
77. R.N. Frank Potential medical therapies for diabetic retinopathy Am J Ophthalmol 133 2002 693 698
78. PKC-DMES Study Group Effect of ruboxistaurin in patients with diabetic macular edema: thirty month results of the PKC-DMES clinical trial Arch Ophthalmol 125 2007 318 324
79. H. Ozaki, H. Hayashi, S.A. Vinores, and et al. Intravitreal sustained release of VEGF causes retinal neovascularization in rabbits and breakdown of the blood-retinal barrier in rabbits and primates Exp Eye Res 64 1997 505 517
80. K. Miyamoto, S. Khosrof, S.E. Bursell, and et al. Vascular endothelial growth factor (VEGF)-induced retinal vascular permeability is mediated by intercellular adhesion molecule-1 (ICAM-1) Am J Pathol 156 2000 1733 1739
81. M.B. Sultan, D. Zhou, J. Loftus Macugen 1013 Study Group A Phase 2/3, multicenter, randomized, double-masked, 2 -year trial of pegaptanib sodium for the treatment of diabetic macular edema Ophthalmology 118 2011 1107 1118
82. D.M. Brown, Q.D. Nguyen, D.M. Marcus RIDE and RISE Research Group Long-term outcome of ranibizumab therapy for diabetic macular edema: 36 month results from two Phase III trials: RISE and RIDE Ophthalmology 120 2013 2013 2022
83. R. Rajendram, S. Fraser-Bell, A. Kaines, and et al. A 2-year prospective, randomized, controlled trial of intravitreal bevacizumab or laser therapy in the management of diabetic macular edema: 24-month data: Report 3 Arch Ophthalmol 130 2012 972 979
84. J.F. Korobelnik, D.V. Do, U. Schmidt-Erfurth, and et al. Intravitreal aflibercept for diabetic macular edema Ophthalmology 121 2014 2247 2254
85. D.R.C.R. Clinical Research Network, J.A. Wells, A.R. Glassman, A.R. Ayala, and et al. Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema N Engl J Med 372 2015 1193 1203
86. L. Jampol, N.B. Bressler, and A.R. Glassman Revolution to a new standard treatment of diabetic macular edema JAMA 311 2014 2269 2270
87. S. Rangasamy, P.G. McGuire, and A. Das Diabetic retinopathy and inflammation: novel therapeutic targets Middle East Afr J Ophthalmol 19 2012 52 59
88. D.S. Boyer, Y.H. Yoon, R. Belfort, and et al. Three-year, randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with diabetic macular edema Ophthalmology 121 2014 1904 1914
89. P. Campochiaro, D.M. Brown, A. Pearson, and et al. Long-term benefit of sustained-delivery fluocinolone acetonide vitreous inserts for diabetic macular edema Ophthalmology 118 2011 626 635
90. A. Thakur, R. Kadam, and U.B. Kompella Trabecular meshwork and lens partitioning of corticosteroids: implications for elevated intraocular pressure and cataracts Arch Ophthalmol 129 2011 914 920
91. A.M. Joussen, V. Poulaki, N. Mitsiades, and et al. Nonsteroidal anti-inflammatory drugs prevent early diabetic retinopathy via TNF-alpha suppression FASEB J 16 2002 438 440
92. E.D. Powell, and R.A. Field Diabetic retinopathy and rheumatoid arthritis Lancet 4 1964 17 18
93. DAMAD Study Group Effect of aspirin alone and aspirin plus dipyridamole in early diabetic retinopathy. A multicenter randomized controlled clinical trial Diabetes 38 1989 491 498
94. ETDRS Group Effects of aspirin treatment on diabetic retinopathy. ETDRS report no. 8. Early Treatment Diabetic Retinopathy Study research group Ophthalmology 98 5Suppl 1991 757 765
95. T.S. Kern, C.M. Miller, T. Du, and et al. Topical administration of nepafenac inhibits diabetes-induced retinal microvascular disease and underlying abnormalities of retinal metabolism and physiology Diabetes 56 2007 373 379
96. S.M. Friedman, T.H. Almukhtar, C.W. Baker, and et al. Topical nepafenac in eyes with noncentral diabetic macular edema Retina 35 2015 944 956
97. Nguyen Q. High Dose Ranibizumab for Diabetic Macular Edema: Month 24 Outcomes of the READ-3 Study (Ranibizumab for Edema of the mAcula in Diabetes - Protocol 3). Abstract. American Society of Retina Specialists Meeting, August 9-13, 2014, San Diego, California.
98. R. Rubio Phase I Clinical Trial Using a Refillable, Non-biodegradable Long-term Drug Delivery Implant of Ranibizumab 2014 World Congress of Ophthalmology Tokyo, Japan
99. P.A. Campochiaro, R. Channa, B.B. Berger, and et al. Treatment of diabetic macular edema with a designed ankyrin repeat protein that binds vascular endothelial growth factor: a phase I/II study Am J Ophthalmol 155 2013 697 704
100. P.U. Dugel, M.S. Blumenkranz, J.A. Haller, and et al. A randomized dose-escalation study of subconjunctival and intravitreal injections of sirolimus in patients with diabetic macular edema Ophthalmology 119 2012 124 131
101. Ohr Pharmaceutical Announces Successful End of Phase II Meeting With the FDA on Squalamine Eye Drops (OHR-102) in Wet AMD. http://www.ohrpharmaceutical.com/media-center/press-releases/detail/304/ohr-pharmaceutical-announces-successful-end-of-phase-ii. Accessed November 3, 2014.
102. L. Scheppke, E. Aguilar, R. Gariano, and et al. Retinal vascular permeability suppression by topical application of a novel VEGFR2/Src kinase inhibitor in mice and rabbits J Clin Invest 118 2008 2337 2346
103. J. Doukas, S. Mahesh, N. Umeda, and et al. Topical administration of a multi-targeted kinase inhibitor suppresses choroidal neovascularization and retinal edema J Cell Physiol 216 2008 29 37
104. Nguyen QD, Schaschar RA, Nduaka CL et al. Dose-ranging evaluation of intravitreal siRNA PF-04523655 for diabetic macular edema (the DEGAS study) Invest Ophthalmol Vis Sci. 2012;53:7666-74.
105. iCo Therapeutics Announces Top-Line Primary Endpoint Data from iCo-007 Phase 2 iDEAL Study in Diabetic Macular Edema. http://icotherapeutics.com/newsroom/index.php?&content-id=211. Accessed November 3, 2014.
106. P.P. Sfikakis, V. Grigoropoulos, I. Emfietzoglou, and et al. Infliximab for diabetic macular edema refractory to laser photocoagulation: a randomized, double-blind, placebo-controlled, cross-over, 32 week study Diabetes Care 33 2010 1523 1528
107. S. Rangasamy, R. Srinivasan, J. Maestas, and et al. A potential role of angiopoietin-2 in the regulation of the blood-retinal barrier in diabetic retinopathy Invest Ophthalmol Vis Sci 52 2011 3784 3791
108. A.M. Joussen, V. Poulaki, A. Tsujikawa, and et al. Suppression of diabetic retinopathy with angiopoietin-1 Am J Pathol 160 2002 1683 1693
109. J. Shen, M. Frye, B.L. Lee, and et al. Targeting VE-PTP activates Tie-2 and stabilizes the ocular vasculature J Clin Invest 124 2014 4564 4576
110. Aerpio Therapeutics Presents Full Results from Phase 1b/2a Study of AKB-9778 for the Treatment of Diabetic Macular Edema. http://aerpio.com/news/Aerpio-ARVO-2014-Data.pdf. Accessed November 3, 2014.
111. A Phase 2, Multi-Center Study To Compare The Efficacy And Safety Of A Chemokine CCR2/5 Receptor Antagonist With Ranibizumab In Adults With Diabetic Macular Edema. ClinicalTrials.gov Identifier: NCT01994291. Accessed November 3, 2014.
112. V.R. Rao, E. Prescott, N.B. Shelke, and et al. Delivery of SAR 1118 to the retina via ophthalmic drops and its effectiveness in a rat streptozotocin (STZ) model of diabetic retinopathy (DR) Invest Ophthalmol Vis Sci 51 2010 5198 5204
113. Efficacy and Safety of Betamethasone Microsphere in Patients With Diabetic Macular Edema (TSUBASA). ClinicalTrials.gov Identifier: NCT01411254. Accessed November 3, 2014.
114. M. Tanito, K. Hara, Y. Takai, and et al. Topical dexamethasone-cyclodextrin microparticle eye drops for diabetic macular edema Invest Ophthalmol Vis Sci 52 2011 7944 7948
115. Phase II clinical trial to evaluate LE-MPP (KPI-121) in patients with retinal vein occlusion and diabetic macular edema. Available at: http://www.kalarx.com/docs/Kala%20Trial%20July%20Initiation%20PR%20Final%207.31.14.pdf. Accessed November 3, 2014.
116. About Optina for the Oral Treatment of Diabetic Macular Edema Available at: http://ampiopharma.com/pipeline/optina/. Accessed November 3, 2014.
117. GSK - Product development pipeline February 2014 Available at: http://www.gsk.com/media/280387/product-pipeline-2014.pdf. Accessed November 3, 2014.
118. C.A. Cukras, P. Petrou, E.Y. Chew, and et al. Oral minocycline for the treatment of diabetic macular edema (DME): results of a Phase I/II clinical study Invest Ophthalmol Vis Sci 53 2012 3865 3874
119. J. Liu, and E.P. Feener Plasma kallikrein-kinin system and diabetic retinopathy Biol Chem 394 2013 319 328
120. KalVista Pharmaceuticals Announces Start of Clinical Development for Novel Treatment for Diabetic Macular Edema. Available at: http://www.kalvista.com/news/44/152/KalVista-Pharmaceuticals-Announces-Start-of-Clinical-Development-for-Novel-Treatment-for-Diabetic-Macular-Edema.html. Accessed November 3, 2014.
121. D. Navaratna, P.G. McGuire, G. Menicucci, and A. Das Proteolytic degradation of VE-cadherin alters the blood-retinal barrier in diabetic retinopathy Diabetes 56 2007 2380 2387
122. Schmidt M, Tisdale A, Lowden P, et al. Optimized IL-6 blockade for the treatment of diabetic macular edema. Abstract. Association for Research in Vision & Ophthalmology (ARVO) Meeting, May 4-8, 2014, Orlando, Florida.
123. Allegro Ophthalmics begins phase 2 clinical trial of Luminate® (Alg-1001) for the treatment of diabetic macular edema. Available at: http://www.allegroeye.com/press/. Accessed January 3, 2014.
124. T. Inoue, M. Morita, T. Tojo, and et al. Novel 1H-imidazol-2-amine derivatives as potent and orally active vascular adhesion protein-1 (VAP-1) inhibitors for diabetic macular edema treatment Bioorg Med Chem 21 2013 3873 3881
125. J.D. Wu, X.H. Xu, J. Zhu, and et al. Effect of exenatide on inflammatory and oxidative stress markers in patients with type 2 diabetes mellitus Diabetes Technol Ther 13 2011 143 148
126. V. Sarao, D. Veritti, and P. Lanzetta Regression of diabetic macular edema after subcutaneous exenatide Acta Diabetol 51 2014 505 508
127. M.C. Hernaez-Ortega, E. Soto-Pedre, and J.A. Piniés Lanreotide Autogel for persistent diabetic macular edema Diabetes Res Clin Pract 80 2008 e8 10
128. P.A. Campochiaro, S.M. Shah, G. Hafiz, and et al. Topical mecamylamine for diabetic macular edema Am J Ophthalmol 149 2010 839 851
129. V. Haurigot, P. Villacampa, A. Ribera, and et al. Increased intraocular insulin-like growth factor-I triggers blood-retinal barrier breakdown J Biol Chem 284 2009 22961 22969
130. A phase 1, open-label safety and pharmacodynamic study of RV 001, an insulin-like growth factor-1 receptor (IGF-1) antagonist, given by IV infusion in patients with center-involved diabetic macular edema (DME). Available at: http://clinicaltrials.gov/show/NCT02103283. Accessed November, 3, 2014.
131. E.A. Friedman, C.D. Brown, and D.H. Berman Erythropoietin in diabetic macular edema and renal insufficiency Am J Kidney Dis 26 1995 202 208
132. W. Li, S.H. Sinclair, and G.T. Xu Effects of intravitreal erythropoietin therapy for patients with chronic and progressive diabetic macular edema Ophthalmic Surg Lasers Imaging 41 2010 18 25
133. N. Lois, R.V. McCarter, C. O'Neill, and et al. Endothelial progenitor cells in diabetic retinopathy Front Endocrinol (Lausanne) 5 2014 44
134. L.C. Shaw, M.B. Neu, and M.B. Grant Cell-based therapies for diabetic retinopathy Curr Diab Rep 11 2011 265 274